3 353

Cited 10 times in

Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients

 Seung Ah Lee  ;  Seung Hyun Hwang  ;  Sung Gwe Ahn  ;  Hak Min Lee  ;  Joon Jeong  ;  Hy-De Lee 
 BREAST CANCER RESEARCH AND TREATMENT, Vol.130(3) : 863-870, 2011 
Journal Title
Issue Date
Adult ; Aged ; Aromatase Inhibitors/adverse effects ; Aromatase Inhibitors/therapeutic use* ; Bone Density/drug effects* ; Bone Density Conservation Agents/therapeutic use* ; Breast Neoplasms/drug therapy* ; Chemotherapy, Adjuvant ; Diphosphonates/therapeutic use* ; Female ; Follow-Up Studies ; Humans ; Imidazoles/therapeutic use* ; Korea ; Middle Aged ; Osteoporosis/chemically induced ; Osteoporosis/prevention & control ; Postmenopause*
Bone loss ; Aromatase inhibitor ; Postmenopausal women ; Bone mineral density ; Zoledronic acid ; Breast cancer
The age distribution of breast cancer patients in Korea, where most are less than 60 years of age and have recently entered menopause, differs from that in the West. The aim of this study was to evaluate bone mineral density (BMD) changes in Korean breast cancer patients treated with an aromatase inhibitor (AI) either alone or in combination with zoledronic acid (ZA). Changes in BMD of the lumbar spine and hip were evaluated in 107 patients receiving AI treatment, of which 59 were treated in combination with ZA. The mean age of the patients was 54.9 years, and the median follow-up period was 38.2 months. With AI treatment alone, BMD loss was significant (all P < 0.0001) in the lumbar spine and hip 12 months (4.18 and 3.95%, respectively), 24 months (6.28 and 5.44%), and 36 months (8.17 and 6.82%) after treatment. In contrast, the combination treatment resulted in increased BMD in the lumbar spine and hip 12 months (2.45 and 0.89%, respectively), 24 months (3.51 and 1.03%), and 36 months (3.85 and 1.80%) after treatment. BMD loss in the lumbar spine was significantly greater in AI alone-treated women who had entered menopause within the past year compared with those who had entered menopause more than 1 year ago, when measured 12 and 24 months after treatment (P = 0.017 and 0.021, respectively). Importantly, ZA effectively inhibited AI-associated bone loss, independent of the postmenopausal interval. Because the proportion of patients in this study who had recently entered menopause was high, bone loss in Korean breast cancer patients treated with AI alone was higher than data reported from the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial. In conclusion, we have shown that ZA is very effective in preventing AI-induced bone loss in Korean postmenopausal breast cancer patients.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Sung Gwe(안성귀) ORCID logo https://orcid.org/0000-0002-8778-9686
Lee, Seung Ah(이승아)
Lee, Hy De(이희대)
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
Hwang, Seung Hyun(황승현)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.